Category Archives: Biosimilars

Guidance on Biosimilar Development Finalized by FDA

Bloomberg BNA posted an overview of the FDA’s guide on biosimilar development. Read the overview here.

Posted in Biosimilars | Leave a comment

Sandoz Launches First Biosimilar Drug in U.S.

A new chapter in the generics/innovator wars began Thursday as Sandoz, Novartis’ generics division launched its Neupogen biosimilar, Zarxio, in the U.S. at about a 15-30% discount from the price of Neupogen. While biosimilars have been marketed in Europe since 2006, Congress … Continue reading

Posted in Biosimilars | Tagged , , , , , , , , , , , | Leave a comment